

RNS Number : 3904O
EKF Diagnostics Holdings PLC
19 September 2013

**EKF Diagnostics Holdings plc
("EKF" or "the Company")**

Investor Results Briefing

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care, central laboratory and molecular diagnostics business, announces it will be hosting an investor briefing on the 8 October where Julian Baines, CEO, and Paul Foulger, Interim FD, will present the Company's financial and operational results for the six months ended 30 June 2013. No new material information will be disclosed.

The event will be held at Rocket, 6 Adams Court, Old Broad Street, London, EC2N 1DX, beginning at 16:15 for a 16:30 start, and will be followed by drinks and canapés.

For more information or to register to attend, contact Walbrook PR (contact details below).

Enquiries:

Walbrook PR Limited

Lianne Cawthorne

Tel: 020 7933 8780 or
ekf@walbrookpr.com

About EKF Diagnostics Holdings plc

EKF Diagnostics Holdings plc was formed in July 2010 following the acquisition of EKF-diagnostic GmbH for €14.32m and refocused its strategy to one of building a substantial point of care diagnostics business. As part of this strategy, the Group has integrated three further acquisitions, Quotient Diagnostics Limited (acquired in October 2010 for a maximum of £5.41m), Argutus Medical Limited (acquired in December 2010 for £2.18m) and Stanbio Laboratory L.P. (acquired in June 2011 for a maximum of US\$25.5m).

The Company, with its head office in Cardiff and operations in London, Germany, Poland, Russia, Ireland and the US, is a leading diagnostics business, focused on the development, production and distribution of chemical reagents and analysers for the testing of Glucose, Lactate, Haemoglobin, Haematocrit and HbA1c.

In May 2011 EKF entered into a distribution agreement with Alere Inc ("Alere"), a global diagnostics company, under which Alere was appointed the exclusive distributor of EKF's CLIA waived Hemo Control device and cuvettes in the US, Canada and United Kingdom. The device is distributed in the US under the name HemoPoint H2.

On the 4 March 2013, EKF announced the establishment of EKF Molecular Diagnostics Ltd to offer innovative products with the potential to change current DNA extraction and detection practices, enabling EKF to address the fast growing companion diagnostics market.

For more information please visit the website: www.ekfdiagnostics.com

This information is provided by RNS
The company news service from the London Stock Exchange

END

MSCQKLBFXKFLBBQ admin Investor Results Briefing 21167024 A Thu, 09/19/2013 - 07:28
Company Announcement - General EKF